MANKIND PHARMA
|
The Current P/E Ratio of MANKIND PHARMA is 54.26.
| Share Price | ₹2,531.2 | Jul 03,2026 |
| Market Cap | ₹104,536.5 Cr | |
| Earnings-TTM | ₹1,926.4 Cr | TTM-Consolidated Results |
| Price/Earnings | 54.26x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of MANKIND PHARMA
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹104,536.5 Cr] as on Jul 03,2026
(/) Earnings [ ₹1,926.4 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 54.26x ]
Thus, for MANKIND PHARMA , the investors are currently willing to pay 54.26 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of MANKIND PHARMA !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of MANKIND PHARMA over the last five years.
Historical PE (Price/Earnings) ratio chart of MANKIND PHARMA
PE Ratio Performance Analysis for MANKIND PHARMA
- MANKIND PHARMA 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 19.67x.
- MANKIND PHARMA 's operated at median p/e ratio of 0x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, MANKIND PHARMA 's p/e ratio peaked in Mar2025 at 50.22x.
- MANKIND PHARMA 's p/e ratio hit its five-year low in Mar2023 of 0x.
How does MANKIND PHARMA 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| MANKIND PHARMA | 1,926.41 | 54.26 | 104,536.5 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 11,564.50 | 39.52 | 456,989.0 |
| DIVIS LABORATORIES LTD | 2,568.00 | 69.89 | 179,471.0 |
| TORRENT PHARMACEUTICALS LTD | 2,138.00 | 75.44 | 161,290.0 |
| CIPLA LTD | 3,869.79 | 30.45 | 117,820.0 |
| DR REDDYS LABORATORIES LTD | 4,144.20 | 27.68 | 114,730.0 |
| LUPIN LTD | 5,355.47 | 21.14 | 113,215.0 |
| ZYDUS LIFESCIENCES LTD | 5,026.40 | 22.64 | 113,815.0 |
| AUROBINDO PHARMA LTD | 3,501.45 | 26.62 | 93,217.0 |
| LAURUS LABS LTD | 889.85 | 93.60 | 83,293.0 |
| BIOCON LTD | 368.80 | 188.36 | 69,465.7 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs MANKIND PHARMA 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 21.14x |
| Max industry PE | 188.36x |
| Median industry PE | 39.52x |
| Average industry PE | 59.05x |
You may also like the below Video Courses